- Home
- IDYA vs MGEE Comparison
IDYA vs MGEE Comparison
Compare IDYA & MGEE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IDYA | MGEE |
|---|---|---|
| Founded | 2015 | 1855 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Electric Utilities: Central |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.9B |
| IPO Year | 2019 | 2001 |
Fundamental Metrics
Financial Performance| Metric | IDYA | MGEE |
|---|---|---|
| Price | $28.22 | $74.11 |
| Analyst Decision | Strong Buy | Sell |
| Analyst Count | 16 | 2 |
| Target Price | $52.86 | ★ $80.50 |
| AVG Volume (30 Days) | ★ 676.7K | 357.6K |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 2.41% |
| EPS Growth | ★ 61.90 | 11.71 |
| EPS | N/A | ★ 1.32 |
| Revenue | ★ $218,710,000.00 | N/A |
| Revenue This Year | N/A | $4.02 |
| Revenue Next Year | $201.05 | $2.77 |
| P/E Ratio | ★ N/A | $56.36 |
| Revenue Growth | ★ 3024.43 | N/A |
| 52 Week Low | $20.47 | $72.16 |
| 52 Week High | $39.28 | $90.66 |
Technical Indicators
Market Signals| Indicator | IDYA | MGEE |
|---|---|---|
| Relative Strength Index (RSI) | 41.29 | 40.70 |
| Support Level | $27.66 | $72.59 |
| Resistance Level | $29.74 | $81.89 |
| Average True Range (ATR) | 1.05 | 1.37 |
| MACD | 0.04 | -0.11 |
| Stochastic Oscillator | 22.94 | 39.66 |
Price Performance
Historical ComparisonAbout IDYA IDEAYA Biosciences Inc.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
About MGEE MGE Energy Inc
MGE Energy provides electric service to 170,000 customers and natural gas service to 180,000 customers in Madison, Wisconsin, and surrounding areas. Nearly 90% of customers are residential. The company also owns a 3.6% stake in American Transmission Co. MGE owns interests in two coal power plants that earn guaranteed fixed rates of return, contributing about 20% of earnings.